BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37743239)

  • 1. Chronic lymphocytic leukaemia Australasian consensus practice statement.
    Anderson MA; Bennett R; Badoux X; Best G; Chia N; Cochrane T; Cull G; Crassini K; Harrup R; Jackson S; Kuss B; Lasica M; Lew TE; Marlton P; Opat S; Palfreyman E; Polizzotto MN; Ratnasingam S; Seymour JF; Soosapilla A; Talaulikar D; Tam CS; Weinkove R; Wight J; Mulligan SP
    Intern Med J; 2023 Sep; 53(9):1678-1691. PubMed ID: 37743239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.
    Di Ciaccio P; McCaughan G; Trotman J; Ho PJ; Cheah CY; Gangatharan S; Wight J; Ku M; Quach H; Gasiorowski R; Polizzotto MN; Prince HM; Mulligan S; Tam CS; Gregory G; Hapgood G; Spencer A; Dickinson M; Latimer M; Johnston A; Armytage T; Lee C; Cochrane T; Berkhahn L; Weinkove R; Doocey R; Harrison SJ; Webber N; Lee HP; Chapman S; Campbell BA; Gibbs SDJ; Hamad N
    Intern Med J; 2020 Jun; 50(6):667-679. PubMed ID: 32415723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
    Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
    J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
    Weinkove R; McQuilten ZK; Adler J; Agar MR; Blyth E; Cheng AC; Conyers R; Haeusler GM; Hardie C; Jackson C; Lane SW; Middlemiss T; Mollee P; Mulligan SP; Ritchie D; Ruka M; Solomon B; Szer J; Thursky KA; Wood EM; Worth LJ; Yong MK; Slavin MA; Teh BW
    Med J Aust; 2020 Jun; 212(10):481-489. PubMed ID: 32401360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Woyach JA
    Am J Hematol; 2022 Nov; 97 Suppl 2(Suppl 2):S11-S18. PubMed ID: 36125037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.
    Alshemmari SH; Siddiqui MA; Pandita R; Osman HY; Cherif H; O'Brien S; Marashi M; Al Farsi K
    Acta Haematol; 2024; 147(3):260-279. PubMed ID: 37751733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
    Eyre TA; Hori S; Munir T
    Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert consensus on the management of chronic lymphocytic leukaemia in Asia.
    Tse E; Kwong YL; Goh YT; Bee PC; Ng SC; Tan D; Caguioa P; Nghia H; Dumagay T; Norasetthada L; Chuncharunee S; Radhakrishnan V; Bagal B; Atmakusuma TD; Mulansari NA
    Clin Exp Med; 2023 Oct; 23(6):2895-2907. PubMed ID: 36795237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Ă–sterborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chronic myeloid leukaemia and chronic lymphocytic leukaemia in five patients, including one with 17p deletion.
    Armarego M; Gottlieb D; Dunlop L; Cooney JP
    Intern Med J; 2021 Apr; 51(4):580-584. PubMed ID: 33890366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Thompson MC; Mato AR
    Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Kuss B; Nagarajan C; Hsieh WS; Cheah CY
    Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
    D'Souza P; Walker G
    Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular pathogenesis and treatment of chronic lymphocytic leukemia].
    Suzuki R
    Rinsho Ketsueki; 2021; 62(8):1085-1093. PubMed ID: 34497195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.
    Molica S; Rossi M; Allsup D
    Acta Haematol; 2024; 147(3):257-259. PubMed ID: 37549650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.
    Yang S; Wei R; Shi H; Wang Y; Lai Y; Zhao X; Lu J; Schmitz N
    Front Oncol; 2024; 14():1396913. PubMed ID: 38835372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.